DUBLIN, January 25, 2023 /PRNewswire/ — The report “Global Orthopedic Oncology Treatment Market: Size, Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022-2030” has been added to from ResearchAndMarkets.com offer.
Global orthopedic oncology treatment market expected to grow 2.5% by 2030
Orthopedic oncology represents a very small percentage in the field of orthopedics due to the fact that the incidence of bone and soft tissue tumors is rare compared to benign tumors of the musculoskeletal system which include trauma, spine, hand and upper limbs, total joints and even pediatric orthopedics.
Sometimes tumors or tumor-like conditions appear in the bones and soft tissues of the musculoskeletal system. This condition is called bone cancer. A medical specialty concerned with the diagnosis and treatment of benign and malignant tumors of bones and soft tissues.
These tumors include Ewing’s sarcoma, osteosarcoma, and other malignancies that involve the musculoskeletal system. Orthopedic oncology is only a small percentage of the field of orthopedics. Even when benign tumors of the musculoskeletal system are included, the incidence of these conditions pales in comparison to trauma, spine, hand and upper limbs, total joints, and even pediatric orthopedics.
However, orthopedic oncology continues to be invigorated by exciting developments and research that have advanced the care of patients with various bone and soft tissue tumors. Further progress has been made in the area of imaging. Computed tomography (CT) is used to identify lung metastases, which can be treated with chemotherapy and/or resection with potential cure in many cases.
Magnetic resonance imaging (MRI) better defines the local extent of disease and avoids metastasis to allow accurate definitive surgery and early detection of local recurrences. Finally, positron emission tomography (PET) proves useful in the detection of local recurrences and can be a valuable predictor of response to chemotherapy in bone and soft tissue malignancies.
Orthopedic oncology represents a very small percentage in the field of orthopedics due to the fact that the incidence of bone and soft tissue tumors is rare compared to benign tumors of the musculoskeletal system which include trauma, spine, hand and upper limb, total joints and even pediatric orthopedics. However, the field of orthopedic oncology continues to be invigorated with exciting research and developments that have improved the standard of treatment and care for patients with various bone and soft tissue tumors.
Currently, most patients with primary bone sarcomas are offered limb salvage surgery without increasing the risk of survival in sarcoma treatment centers. Additionally, advances in imaging techniques and surgical techniques have further improved the treatment of patients with bone and soft tissue malignancies. Orthopedic oncologists continue to collaborate with other subspecialists to incorporate advances in surgical techniques. This is especially true for the development of implants and image-guided surgery.
The global orthopedic oncology treatment market on type of procedures has been segmented into soft tissue excisions/resections, limb salvage surgery, amputation, adjuvant chemotherapy, and reconstructive surgery. Reconstructive surgery is further sub-segmented into hip and joint replacements and bone grafts.
The dominant segment is reconstructive surgery
Reconstructive surgery holds the largest share of the global orthopedic oncology treatment market. Bone grafting techniques are expected to grow at the highest rate during the forecast period owing to advancements in the field of prosthetics and stents.
Latin Americathem Middle Eastand Africa have become the most potential market
Baseline 2020, Asia Pacific has been observed as the largest market for the orthopedic oncology market. The high prevalence of the disease along with the growing healthcare ecosystem in the region has contributed to the growth of the orthopedic oncology market in Asia Pacific.
Additionally, the growth of medical tourism in the region over the past decade has further fueled the orthopedic oncology treatment market by Asia Pacific. Latin Americathem Middle Eastand Africa emerged as the most potential market due to the high prevalence of osteosarcoma and low treatment options available in the region. Hence, this market would exhibit a strong growth rate over the forecast period with the development of healthcare infrastructure.
Historical and forecast period
This report represents an analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compound annual growth rate (CAGR) for each of the respective segments estimated for the forecast period from 2022 to 2030.
The current report includes quantitative market estimates for each micromarket for each geographical region and qualitative market analysis such as micro and macro environmental analysis, market trends, competitive intelligence, segment analysis, the carriers’ five-force model, the most winning strategies, the main investment markets, emerging markets. technology trends and analysis, case studies, strategic findings and recommendations, and other key market insights.
Key questions answered by this report
- What are the key micro and macro environmental factors impacting the growth of the Oncology Orthopedic Treatment Market?
- What are the major investment pockets with respect to product segments and geographies currently and during the forecast period?
- Estimated forecasts and market projections till 2030.
- Which segment represents the fastest CAGR during the forecast period?
- Which market segment has a larger market share and why?
- Are low- and middle-income economies investing in the orthopedic oncology treatment market?
- What is the largest regional market for the Orthopedic Oncology Treatment market?
- What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin Americaand Middle East & Africa?
- What are the key trends driving the growth of the Oncology Orthopedic Treatment Market?
- Who are the major competitors and what are their key strategies to strengthen their presence in the global orthopedic oncology treatment market?
Main topics covered:
1. Preface
2. Executive Summary
3. Orthopedic Oncology Treatment Market: Business Outlook and Market Dynamics
3.1. Introduction
3.2. Global Orthopedic Oncology Treatment Market Value, 2020-2030, (USD Million)
3.3. Market dynamics
3.3.1. Market factors
3.3.2. Market constraints
3.3.3. Main challenges
3.3.4. Key Opportunities
3.4. Impact analysis of drivers and constraints
3.5. Sawtooth analysis
3.6. Porter’s five-force model
3.6.1. Supplier Power
3.6.2. purchasing power
3.6.3. The threat of substitutes
3.6.4. The threat of new entrants
3.6.5. Competitive Rivalry
3.7. PESTEL analysis
3.7.1. The political landscape
3.7.2. Economic Landscape
3.7.3. Technological landscape
3.7.4. Legal landscape
3.7.5. Social landscape
4. Orthopedic Oncology Treatment Market: By Procedure Type, 2020-2030, USD (Million)
4.1. Market overview
4.2. Growth and Revenue Analysis: 2021 vs. 2030
4.3. Market segmentation
4.3.1. Soft tissue excisions/resections
4.3.2. Limb salvage surgery
4.3.3. Amputation
4.3.4. Adjuvant chemotherapy
4.3.5. reconstructive surgery
4.3.5.1. Hip and joint replacement
4.3.5.2. Bone grafts
5. North America Orthopedic Oncology Treatment Market, 2020-2030, USD (Million)
6. UK & EU Orthopedic Oncology Treatment Market, 2020-2030, USD (Million)
7. Asia-Pacific Orthopedic Oncology Treatment Market, 2020-2030, USD (Million)
8. Latin America Orthopedic Oncology Treatment Market, 2020-2030, USD (Million)
9. Middle East and Orthopedic Oncology Treatment Market in Africa, 2020-2030, USD (Million)
10. Company Profiles
10.1. Stryker Company
10.1.1. Company presentation
10.1.2. Financial performance
10.1.3. Product portfolio
10.1.4. Strategic initiatives
10.2. Zimmer Biomet Holdings, Inc.
10.2.1. Company presentation
10.2.2. Financial performance
10.2.3. Product portfolio
10.2.4. Strategic initiatives
10.3. Smith & Nephew plc
10.3.1. Company presentation
10.3.2. Financial performance
10.3.3. Product portfolio
10.3.4. Strategic initiatives
10.4. DePuy Synthes (Johnson & Johnson)
10.4.1. Company presentation
10.4.2. Financial performance
10.4.3. Product portfolio
10.4.4. Strategic initiatives
10.5. Medtronic
10.5.1. Company presentation
10.5.2. Financial performance
10.5.3. Product portfolio
10.5.4. Strategic initiatives
10.6. Medical Focus
10.6.1. Company presentation
10.6.2. Financial performance
10.6.3. Product portfolio
10.6.4. Strategic initiatives
10.7. Roche Holding SA
10.7.1. Company presentation
10.7.2. Financial performance
10.7.3. Product portfolio
10.7.4. Strategic initiatives
10.8. Amgen, Inc.
10.8.1. Company presentation
10.8.2. Financial performance
10.8.3. Product portfolio
10.8.4. Strategic initiatives
10.9. Novartis AG
10.9.1. Company presentation
10.9.2. Financial performance
10.9.3. Product portfolio
10.9.4. Strategic initiatives
10.10. GlaxoSmithKline
10.10.1. Company presentation
10.10.2. Financial performance
10.10.3. Product portfolio
10.10.4. Strategic initiatives
10.11. Sanofi
10.11.1. Company presentation
10.11.2. Financial performance
10.11.3. Product portfolio
10.11.4. Strategic initiatives
10.12. Pfizer Inc.
10.12.1. Company presentation
10.12.2. Financial performance
10.12.3. Product portfolio
10.12.4. Strategic initiatives
For more information about this report, visit https://www.researchandmarkets.com/r/jtq4tr-orthopedic?w=5
Media Contact:
Research and Markets
Laura Woodsenior
[email protected]
For EST office hours, call +1-917-300-0470
For USA/CAN call toll free +1-800-526-8630
For GMT office hours call +353-1-416-8900
US Fax: 646-607-1907
Fax (outside the US): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets
